Inotiv, Inc. Company Profile
Background
Inotiv, Inc., established in 1974 as Bioanalytical Systems, Inc., is a contract research organization (CRO) headquartered in West Lafayette, Indiana. The company specializes in nonclinical and analytical drug discovery and development services, as well as providing research models and related products. In March 2021, Bioanalytical Systems, Inc. rebranded to Inotiv, Inc. to better reflect its expanded service offerings.
Key Strategic Focus
Inotiv operates through two primary business units:
- Discovery and Safety Assessment (DSA): This segment offers a comprehensive suite of nonclinical and analytical services, including general toxicology, pathology, bioanalysis, and drug metabolism and pharmacokinetics (DMPK). These services support pharmaceutical and medical device companies in the early stages of drug development.
- Research Models and Services (RMS): This unit provides a broad range of research models, such as rodents, rabbits, and non-human primates, along with lab animal diets, bedding, and support services. These offerings are essential for preclinical research and testing.
Inotiv's strategic focus is to deliver integrated solutions that enhance efficiency, improve data quality, and reduce the cost of bringing new drugs and medical devices to market. The company emphasizes client-centric scientific continuity and has a long history of regulatory compliance.
Financials and Funding
As of December 24, 2025, Inotiv's stock (NASDAQ: NOTV) is trading at $0.6385 per share, reflecting a market capitalization of approximately $22.24 million. The company reported a consolidated net loss of $108.9 million for the fiscal year 2024 and a net loss of $27.6 million in the first quarter of fiscal year 2025, partly due to reduced non-human primate pricing.
Inotiv has pursued strategic acquisitions to expand its capabilities. In November 2021, the company acquired Envigo RMS Holding Corp., enhancing its research models and services segment. In April 2021, Inotiv secured $28.0 million in debt financing from First Internet Bank of Indiana and completed the acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc., expanding its nonclinical pharmacology and histopathology services.
Pipeline Development
Inotiv's pipeline development focuses on providing comprehensive nonclinical and analytical services to support drug discovery and development. The company offers a range of services from early discovery through preclinical development, including toxicology studies, pathology, bioanalysis, and DMPK. These services are designed to assist clients in advancing their drug candidates through the investigational new drug (IND) application process and beyond.
Technological Platform and Innovation
Inotiv leverages several proprietary technologies and scientific methodologies to differentiate itself in the industry:
- Proprietary Technologies: The company utilizes advanced in vivo sampling systems and offers a range of research models, including genetically engineered models and services (GEMS), contract breeding services, and Teklad laboratory animal diets.
- Significant Scientific Methods: Inotiv employs state-of-the-art facilities and experienced scientists to deliver a comprehensive range of nonclinical and analytical/bioanalytical services. The company emphasizes client value through direct resource allocation, experienced scientific guidance, and innovative methodologies.
Leadership Team
Inotiv's leadership team includes:
- Robert W. Leasure, Jr.: President and Chief Executive Officer. Leasure has been with Inotiv since 2018 and has played a pivotal role in the company's strategic direction and growth initiatives.
- Beth A. Taylor: Chief Financial Officer. Taylor joined Inotiv in 2019 and has been instrumental in managing the company's financial operations and strategic financial planning.
- Andrea Castetter: Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer. Castetter has been with Inotiv since 2019, overseeing legal affairs and ensuring regulatory compliance across the organization.
- Jeffrey Arthur Krupp: Chief Human Resources Officer. Krupp joined Inotiv in 2020, focusing on talent management and organizational development to support the company's growth and operational efficiency.
Leadership Changes
In April 2021, Inotiv announced plans to expand its St. Louis operations to provide more comprehensive and integrated services, particularly in support of the company's acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc. This expansion aimed to enhance the company's capabilities in pharmacology, toxicology, DMPK, histology, pathology, and cell and molecular biology.
Competitor Profile
Market Insights and Dynamics
The contract research organization (CRO) market is characterized by a diverse range of service providers offering nonclinical and analytical services to pharmaceutical and biotech companies. Key competitors in this space include:
- Charles River Laboratories (CRL): A dominant player in preclinical CRO services with a market capitalization exceeding $10 billion. CRL offers a comprehensive service portfolio and has a global reach, making it a formidable competitor.
- ICON plc (ICLR): With a market capitalization over $17 billion, ICON provides deep clinical and preclinical capabilities, posing significant competition to Inotiv.
- Thermo Fisher Scientific (TMO): Primarily an instrumentation company, Thermo Fisher's Patheon and PPD CRO divisions compete in analytical services, leveraging vast resources and cross-selling opportunities.
- Waters Corporation (WAT): A pure-play analytical instruments competitor to Inotiv's Research Products segment, Waters dominates HPLC and mass spectrometry markets.
Strategic Collaborations and Partnerships
In November 2021, Inotiv acquired Envigo RMS Holding Corp., enhancing its research models and services segment. This acquisition integrated Envigo's extensive range of research models and related services with Inotiv's nonclinical and analytical services, creating a comprehensive contract pharmaceutical research solutions provider.
Operational Insights
Inotiv's strategic initiatives include optimizing its global footprint and streamlining operations. In August 2023, the company sold its Israeli businesses to Harlan Holdings Ltd., receiving approximately $1.2 million in cash and a note receivable of around $2.5 million. This sale was part of Inotiv's site optimization plan for the Research Models and Services segment.
Strategic Opportunities and Future Directions
Inotiv is focused on expanding its service offerings and global presence through strategic acquisitions and operational optimizations. The company aims to enhance its capabilities in nonclinical and analytical services, as well as research models and related products, to better serve its clients in the pharmaceutical and biotech industries.
Social Media Presence
- LinkedIn: Inotiv, Inc.
- Twitter: @InotivInc
- Facebook: Inotiv, Inc.
